Dr Jack Mosley researched GLP-1 drug brands including Ozempic with his father and has written the book Food Noise.

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...

Michael Mosley’s son follows in his footsteps by writing book on weight-loss drugs - The late TV doctor’s family are ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...

The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the Danish company behind Wegovy, ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

LifeMD, a virtual primary care services provider, said it is integrating with Gifthealth which will make Lilly's single-dose vials of Zepbound accessible to the company's eligible patients.

The FDA recently announced that Novo Nordisk’s semaglutide GLP-1 medication (Ozempic and Wegovy) is no longer in short supply ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...